Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837450 | 0.82 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL18263847 | 0.81 | SLC6A2 (0.60) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27815200 | 0.80 | SLC6A2 (0.54) | SLC6A4SLC6A2OPRD1OPRM1OPRK1 | |
| SCHEMBL4491354 | 0.80 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL12232428 | 0.80 | SLC6A2 (0.57) | SLC6A4SLC6A2OPRD1OPRM1SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL31055380 | 0.79 | SLC6A2 (0.50) | SLC6A4SLC6A2CYP3A4CYP2C19SLC6A3 | |
| SCHEMBL6156471 | 0.79 | JAK3 (0.40) | SLC6A4SLC6A2OPRD1OPRM1OPRK1 | |
| SCHEMBL3839881 | 0.76 | SLC6A2 (0.57) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL18270999 | 0.76 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL16503429 | 0.76 | SLC6A2 (0.57) | SLC6A4SLC6A2OPRD1OPRM1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226933-B2 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-7186733-B2 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-7064137-B2 | Analgesics; anxiolytic agents; gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| US-7008952-B2 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| CN-1639123-A | 4- (phenyl- (piperidin-4-yl) -amino) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-07-13 | — | — | CN | disclosed |
| CN-1639123-A | 4- (phenyl- (piperidin-4-yl) -amino) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-07-13 | — | — | CN | disclosed |
| CN-1620435-A | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | CN | disclosed |
| CN-1620435-A | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | CN | disclosed |
| US-20040235897-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | BROWN WILLIAM (CA) | 2004-11-25 | — | — | US | disclosed |
| CN-1541203-A | 4- (phenyl- (piperidin-4 yl) -amino) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | — | 2004-10-27 | — | — | CN | disclosed |
| EP-1395556-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1395557-A1 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1395557-A1 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1395558-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1395555-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERATIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094784-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094785-A1 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094785-A1 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094782-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERATIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094783-A1 | 4-(PHENYL-(PIPERIDIN-4-YL)-AMINO)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235897-A1 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR1D, HTR2C, HTR3C | SLC6A4 675/4885SLC6A2 1183/4885OPRD1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.